Source comparison
MK-677 Long Term Use Safe 12 Months: Comparison of Dosing Protocols
The table below compares clinical dosing strategies for MK-677 over 12 months, based on published trial data and observed metabolic outcomes. 25mg daily continuous +84% at 12 months +7.2 mg/dL 22% Grade 1–2 Standard clinical dose. Maximum GH elevation but high
This comparison does not assign a generated winner or score.
- The table below compares clinical dosing strategies for MK-677 over 12 months, based on published trial data and observed metabolic outcomes.
- 25mg daily continuous
- +84% at 12 months
- +7.2 mg/dL
- 22% Grade 1–2
- Standard clinical dose. Maximum GH elevation but highest metabolic impact. Requires glucose monitoring after month 6.
- 12.5mg daily continuous
- +52% at 12 months
- +3.1 mg/dL
- 9% Grade 1
- Lower-dose alternative. Retains most anabolic benefit with reduced side effect burden. Best for individuals with insulin sensitivity concerns.
- 25mg 5 days on / 2 days off
- +68% at 12 months
- +4.8 mg/dL
- 14% Grade 1
- Intermittent protocol. Preserves IGF-1 elevation while allowing metabolic recovery periods. Reduces cumulative glucose impact.
- 25mg daily with metformin 500mg
- +79% at 12 months
- +1.9 mg/dL
- 20% Grade 1
- Metformin co-administration blunts insulin resistance without affecting GH secretion. Used in research settings to mitigate glucose effects.